임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 2상모집 예정· Lung Cancer (NSCLC)절제 가능한 고PD-L1 비소세포폐암에 대한 수술 전후 세미플리맙 투여
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
협력: 리제네론
- 2상모집 예정· Ebola Virus Disease건강한 지원자에서 인마젭 투여와 에르베보 백신 접종 사이의 시간 간격이 백신 면역반응에 미치는 영향
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
협력: 리제네론
- 3상모집 예정· Venous Thromboembolism (VTE)Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
리드: 리제네론
- 단계 미표기모집 예정· Conjunctivitis AllergicA Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
리드: 리제네론
- 1/2상모집 예정· Ovarian CancerSafety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
협력: 리제네론
- 2상모집 중· Colon and Rectal CancerGemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
협력: 리제네론
- 2상모집 중· Non-small Cell Lung Cancer Stage IIINeoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
협력: 리제네론
- 3상모집 예정· Atrial Fibrillation (AF)Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
리드: 리제네론
- 3상모집 예정· Fibrodysplasia Ossificans Progressiva (FOP)A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
리드: 리제네론
- 3상모집 중· Peripheral Artery Disease (PAD)Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
리드: 리제네론
- 2상모집 예정· Overweight or ObesityStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
리드: 리제네론
- 1/2상모집 예정· Primary Open Angle Glaucoma (POAG)REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
리드: 리제네론
- 4상모집 예정· Relapsed/Refractory Multiple Myeloma (RRMM)Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
리드: 리제네론
- 2상모집 예정· Metabolic Dysfunction-Associated Steatohepatitis (MASH)Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
리드: 리제네론
- 2상모집 예정· Bladder Urothelial CarcinomaA Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
협력: 리제네론
- 1상모집 예정· Hepatocellular CarcinomaCemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
협력: 리제네론
- 1상모집 예정· Nasopharyngeal CarcinomaA Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
협력: 리제네론
- 3상모집 중· Venous Thromboembolism (VTE)Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
리드: 리제네론
- 4상모집 예정· Chronic Obstructive Pulmonary Disease (COPD)This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
리드: 리제네론 · 협력: 사노피
- 1상모집 중· Overweight or ObesitySafety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
리드: 리제네론
- 2상모집 중· HypercholesterolemiaA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
리드: 리제네론
- 3상모집 중· Paroxysmal Nocturnal HemoglobinuriaA Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
리드: 리제네론
- 2상모집 중· Merkel Cell Carcinoma, Stage INeoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
협력: 리제네론
- 1/2상모집 예정· Metastatic Castration-Resistant Prostate Cancer (mCRPC)REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
리드: 리제네론
- 1상모집 중· Healthy VolunteerFirst-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
리드: 리제네론
- 2상모집 중· Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
리드: 리제네론
- 3상모집 중· High Risk Smoldering Multiple Myeloma (HR-SMM)A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
리드: 리제네론
- 4상모집 중· Polymyalgia RheumaticaSarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
리드: 사노피 · 협력: 리제네론
- 3상모집 예정· Chronic Rhinosinusitis With Nasal PolypsA Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
리드: 사노피 · 협력: 리제네론
- 2상모집 중· Pulmonary Arterial Hypertension (PAH)Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
리드: 리제네론
- 2상모집 중· Pancreatic Ductal Adenocarcinoma (mPDAC)Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
협력: 리제네론
- 2상모집 중· Advanced Renal Cell Carcinoma (aRCC)A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
협력: 리제네론
- 2상모집 중· Head and Neck Squamous Cell Carcinoma (HNSCC)A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
리드: 리제네론
- 3상모집 중· Atrial Fibrillation (AF)Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
리드: 리제네론
- 1/2상모집 중· Relapsed Refractory Multiple Myeloma (RRMM)A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
리드: 리제네론
- 1/2상모집 중· Recurrent Multiple MyelomaResponse-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
협력: 리제네론
- 2상모집 중· Advanced/Metastatic Non-Small Cell Lung CancerA Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
리드: 리제네론
- 단계 미표기모집 중· Chronic Spontaneous UrticariaA Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
리드: 사노피 · 협력: 리제네론
- 2상모집 중단 (진행 중)· Overweight or ObesityStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
리드: 리제네론
- 3상모집 중· Generalized LipodystrophyEfficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
리드: 리제네론
- 3상초청 등록· Chronic Rhinosinusitis With Nasal PolypsAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
리드: 사노피 · 협력: 리제네론
- 2상모집 중· Functional Hypothalamic Amenorrhea (FHA)A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
리드: 리제네론
- 3상모집 중· Cancer-Associated Thrombosis (CAT)REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
리드: 리제네론
- 단계 미표기모집 중· Atopic DermatitisThe Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
리드: 사노피 · 협력: 리제네론
- 1/2상모집 중· Paroxysmal Nocturnal Hemoglobinuria (PNH)A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
리드: 리제네론
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.